Satralizumab
Satralizumab (INN;[1] formerly sapelizumab; development code development code SA237) is a humanized monoclonal antibody that is being investigated for the treatment of neuromyelitis optica spectrum disorder.[2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | interleukin 6 receptor |
Clinical data | |
Other names | SA237 |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6340H9776N1684O2022S46 |
Molar mass | 143416.47 g·mol−1 |
This drug is being developed by Chugai Pharmaceutical, a member of the Roche Group. As of 2018, satralizumab is undergoing Phase III trials.[3]
References
- World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Satralizumab, American Medical Association.
- "Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018".
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.